BeOne Medicines Receives FDA Approval for Blood Cancer Drug
The FDA granted accelerated approval to BeOne Medicines' Beqalzi for treating relapsed mantle cell lymphoma. The drug is expected to launch later this year.
Xurve View
Insights:
Xurve View
BeOne Medicines secured United States FDA approval for its blood cancer drug Beqalzi on Wednesday. The drug treats relapsed or refractory mantle cell lymphoma, an aggressive lymphatic system cancer. The approval expands Beqalzi's reach into a market with 3,300 new diagnoses annually.
